PAN 90806

Drug Profile

PAN 90806

Alternative Names: CP-547,632; CP-632; OSI-632; PAN90806

Latest Information Update: 31 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator OSI Pharmaceuticals; Pfizer
  • Developer PanOptica; Pfizer
  • Class Antineoplastics; Eye disorder therapies; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Wet age-related macular degeneration
  • Phase I Diabetic retinopathy
  • Discontinued Non-small cell lung cancer; Ovarian cancer

Most Recent Events

  • 22 May 2018 Phase-I/II clinical trials in Wet age-related macular degeneration (In the elderly) in European Union (Ophthalmic)
  • 30 Apr 2018 PanOptica files amendments in IND application with the US FDA and CTA applications in the EU for Wet age-related macular degeneration
  • 26 Apr 2018 PanOptica initiates enrolment in a phase I/II trial for Wet age-related macular degeneration in USA (NCT03479372)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top